Events - Pharvaris N.V.

Past Events

Oct 10 - Oct 12, 2025

2025 HAE International (HAEi) Regional Conference EMEA

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study 437 KB

Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life and Disease Control in Participants with Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study 551 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 300.3 KB

Durability of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks 292.2 KB

Efficacy and Safety of Oral Deucrictibant for Prophylaxis and On-Demand Treatment of Attacks in Acquired Angioedema with C1 Inhibitor Deficiency: CREAATE Phase 3 Trial Design 255.5 KB

Clinical Validation of a Novel Biomarker Assay to Characterize Bradykinin-Mediated Angioedema in Prospective and Biobank Plasma Samples 563.9 KB

Oct 3 - Oct 5, 2025

Joint XXXVII Italian Society of Allergology, Asthma, and Clinical Immunology (SIAAIC) National Congress and World Allergy Organization Congress (WAO)

Supporting Materials

Efficacy and Safety of Oral Deucrictibant for Prophylaxis and On-Demand Treatment of Attacks in Acquired Angioedema with C1 Inhibitor Deficiency: CREAATE Phase 3 Trial Design 185 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study 233.6 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 167.6 KB

Oct 2 - Oct 4, 2025

Deutscher Allergiekongress (DAK)

Supporting Materials

Durability of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks 1.4 MB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 1.8 MB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study 1.5 MB

Oct 1 - Oct 4, 2025

Spanish Society of Allergology and Clinical Immunology (SEAIC)

Supporting Materials

Acquired Angioedema Due to C1-Inhibitor Deficiency: Conceptual Model of Patient Experience and Assessment of Patient-Reported Outcome Measures 334.3 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for the Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 1 MB

Durability of Response to a Single Dose of Oral Deucrictibant for the On-Demand Treatment of Hereditary Angioedema Attacks 979.3 KB

Sep 26 - Sep 28, 2025

Consortium of Independent Immunology Clinics (CIIC) Fall 2025 Conference

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study and Post-hoc Analysis on Durability of Response to a Single Dose of Oral Deucrictibant 345.5 KB

Long-Term Safety, Efficacy and Sustained Therapeutic Exposure of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension and Results of a Pharmacokinetics Study in Healthy Volunteers 1.3 MB

Sep 10, 2025 8:30 AM EDT

Morgan Stanley 23rd Annual Global Healthcare Conference

Click for Webcast

Sep 9, 2025 8:00 AM EDT

H.C. Wainwright 27th Annual Global Investment Conference

Click for Webcast

Sep 4, 2025 3:45 PM EDT

2025 Wells Fargo Healthcare Conference

Click for Webcast

Sep 3, 2025 11:30 AM EDT

Cantor Global Healthcare Conference 2025

Click for Webcast

Aug 27 - Aug 29, 2025

European Academy of Allergy & Clinical Immunology (EAACI) Hong Kong Allergy School 2025

Supporting Materials

Efficacy and Safety of Oral Deucrictibant for Prophylactic (CHAPTER-3) and for On-Demand (RAPIDe-3) Treatment of Hereditary Angioedema Attacks in Adolescents and Adults: Two Phase 3 Trial Designs 925.1 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylactic and On-Demand Treatment of Hereditary Angioedema Attacks: Results of the CHAPTER-1 and RAPIDe-2 Extension Trials 1.2 MB

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
…
Next page
Last page

Presentations

Source:

EAACI Annual Congress 2026, Istanbul, Turkey

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial

Source:

EAACI Annual Congress 2026, Istanbul, Turkey

A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema

Source:

EAACI Annual Congress 2026, Istanbul, Turkey

Clinical Cardiovascular Safety Assessment of Oral Deucrictibant

Latest Corporate Presentation